相关实验视频

Updated: Sep 13, 2025

Transgenic Rodent Assay for Quantifying Male Germ Cell Mutant Frequency

Transgenic Rodent Assay for Quantifying Male Germ Cell Mutant Frequency

Published on: August 6, 2014

使用Hawk-SeqTM的全基因组突变性评估表明了高的实验室间可重复性和与转基因动物基因突变试验的一致性

Shoji Matsumura¹, Sayaka Hosoi², Takako Hirose²

¹R&D -Safety Science Research, Kao Corporation, 3-25-14 Tonomachi, Kawasaki-ku, Kawasaki-shi, Kanagawa, 210-0821, Japan. matsumura.shouji@kao.com.

Genes and environment : the official journal of the Japanese Environmental Mutagen Society

|July 29, 2025

概括

霍克-SeqTM,一个错误纠正的下一代测序 (ecNGS) 方法,显示高可重现性和一致性与转基因动物突变试验检测化学突变. 这种ecNGS试验为致变性检测提供了可靠的替代方案.

科学领域:

基因组学就是基因组学.
毒理学毒理学毒理学
分子生物学分子生物学

背景情况:

错误纠正下一代测序 (ecNGS) 提供了对化学诱导突变的敏感检测.
霍克-SeqTM是一种已建立的ecNGS方法,用于定性和定量突变致病性评估.
评估实验室间可重复性对于采用新的ecNGS检测方法至关重要.

研究的目的:

评估Hawk-SeqTM方法的实验室间可复制性.
评估霍克-SeqTM与转基因动物 (TGR) 突变试验的一致性.
支持采用ecNGS测试作为传统方法的替代方法.

主要方法:

霍克-SeqTM协议被转移到两个独立的实验室.
分析了暴露于[a]pyrene (BP),N-乙基-N-氨酸urea (ENU) 和N-甲基-N-氨酸urea (MNU) 的gpt三角洲小鼠的基因组DNA.
在实验室中分析了突变频率,并与TGR测定数据进行了比较.

主要成果:

在所有实验室中成功转移协议并一致检测剂量依赖突变.
观察到高可重现性,相关系数 (r2) 超过0.97的基础替换频率.
霍克-SeqTM显示了与TGR测定结果的正相关性 (r2 = 0.64),不同的变异原体具有不同的折叠诱导模式.

结论:

霍克-SeqTM证明了强大的实验室间可重复性,用于全基因组突变性评估.
该方法与gpt试验具有很好的一致性,支持其实用性.
霍克-SeqTM为突变致病性测试提供了TGR试验的合适和潜在的改进替代方案.

关键词:

错误纠正的下一代测序的错误纠正霍克-Seq TM TM 是一个.突变性测定试验突变性测定试验可复制性可复制性可转让性可转让性转基因动物模型模型验证研究的验证研究.

更多相关视频

The Lambda Select cII Mutation Detection System

The Lambda Select cII Mutation Detection System

Published on: April 26, 2018

Identifying DNA Mutations in Purified Hematopoietic Stem/Progenitor Cells

Identifying DNA Mutations in Purified Hematopoietic Stem/Progenitor Cells

Published on: February 24, 2014

相关概念视频

In-vitro Mutagenesis

In-vitro Mutagenesis

To learn more about the function of a gene, researchers can observe what happens when the gene is inactivated or “knocked out,” by creating genetically engineered knockout animals. Knockout mice have been particularly useful as models for human diseases such as cancer, Parkinson’s disease, and diabetes.

Mutagenicity and Carcinogenicity

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...